Carlsmed (NASDAQ:CARL) Shares Up 7.8% – Here’s Why

Carlsmed, Inc. (NASDAQ:CARL – Get Free Report)’s stock price traded up 7.8% during trading on Monday. The company traded as high as $18.22 and last traded at $18.4550. Approximately 43,340 shares traded hands during trading, a decline of 68% from the average daily volume of 135,142 shares. The stock had previously closed at $17.12.

Analyst Upgrades and Downgrades

CARL has been the subject of several research analyst reports. Needham & Company LLC increased their price objective on Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Truist Financial upped their target price on shares of Carlsmed from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Finally, BTIG Research increased their target price on Carlsmed from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, November 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Check Out Our Latest Stock Report on CARL

Carlsmed Price Performance

The company has a market capitalization of $489.50 million, a price-to-earnings ratio of -12.07 and a beta of 1.97. The company has a 50-day moving average price of $15.05 and a 200-day moving average price of $12.63. The company has a debt-to-equity ratio of 0.20, a quick ratio of 5.62 and a current ratio of 5.79.

Carlsmed (NASDAQ:CARL – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The firm had revenue of $21.55 million during the quarter. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. On average, equities research analysts expect that Carlsmed, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new position in shares of Carlsmed during the 2nd quarter worth approximately $12,992,000. Janus Henderson Group PLC lifted its stake in Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock valued at $11,108,000 after acquiring an additional 86,834 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of Carlsmed during the 2nd quarter worth approximately $6,200,000. BlackRock Inc. bought a new stake in shares of Carlsmed during the 2nd quarter worth about $5,528,000. Finally, Russell Investments Group Ltd. lifted its position in Carlsmed by 85.3% during the third quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock worth $3,627,000 after acquiring an additional 118,663 shares during the last quarter.

Carlsmed Company Profile

(Get Free Report)

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.

Featured Articles

Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.